Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 20/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 20/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 20/20 | 0.46 |
| ▸ | CASP1 | P29466 | 17/20 | 0.46 |
| ▸ | CASP7 | P55210 | 17/20 | 0.46 |
| ▸ | HPGD | P15428 | 12/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 10/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.41 |
| ▸ | GLA | P06280 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8810291 | 0.91 | HSD17B10 (0.40) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| Maleic Acid SCHEMBL8810283 | 0.91 | HSD17B10 (0.40) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1922986 | 0.86 | POLB (0.42) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL8809105 | 0.77 | HTT (0.51) | ALDH1A1HSD17B10CASP1HPGDTSHR | |
| SCHEMBL1846525 | 0.75 | ALDH1A1 (0.44) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1847339 | 0.73 | ALDH1A1 (0.48) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL4426668 | 0.73 | CYP1A2 (0.43) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1847875 | 0.71 | MARK3 (0.59) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 | |
| SCHEMBL1845320 | 0.70 | POLB (0.39) | ALDH1A1CYP1A2HSD17B10CASP1TSHR | |
| SCHEMBL1847690 | 0.68 | ALDH1A1 (0.46) | ALDH1A1CYP1A2HSD17B10CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2324023-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2009070164-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA (US) | 2009-06-04 | — | — | WO | claimed |
| US-20080124306-A1 | Vigor Enhancement Via Administration of Pyrimidine Derivatives | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2008-05-29 | — | — | US | claimed |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | Progenicyte Therapeutics, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20200246334-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20190167674-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20180092913-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2018-04-05 | — | — | US | disclosed |
| EP-2326330-B1 | COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS | UNIV CENTRAL FLORIDA RES FOUND (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8791128-B2 | Compositions for treating or delaying the onset of hair loss | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110190320-A1 | Compositions for Treating or Delaying the Onset of Hair Loss | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20080124306-A1 | Vigor Enhancement Via Administration of Pyrimidine Derivatives | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2008-05-29 | — | — | US | disclosed |
| EP-1890673-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSMIP Assets B.V. (NL) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133876-A1 | USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES | DSM IP ASSETS B.V. (NL) | 2006-12-21 | — | — | WO | disclosed |
| US-5976523-A | PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES | MITSUI PHARMACEUTICALS, INC. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0257102-B1 | AGENTS FOR TREATING NEUROPHATHY | MITSUI PETROCHEMICAL IND (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0799617-A2 | Therapeutic agent for neurological diseases | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-08 | — | — | EP | disclosed |
| EP-0743066-A2 | Wound-healing agent | MITSUI PHARMACEUTICALS, INC. (JP) | 1996-11-20 | — | — | EP | disclosed |
| US-4959368-A | PYRIMIDINE DERIVATIVES | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1990-09-25 | — | — | US | disclosed |
| EP-0257102-A1 | AGENTS FOR TREATING NEUROPHATHY | Mitsui Chemicals, Inc. (JP) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124306-A1 | Vigor Enhancement Via Administration of Pyrimidine Derivatives | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20190167674-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20210046079-A1 | COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS | PSEN1, PSEN2, NES | ALDH1A1 4397/4885CYP1A2 4466/4885HSD17B10 873/4885 |
| US-20110190320-A1 | Compositions for Treating or Delaying the Onset of Hair Loss | SHBG, CYP19A1, TYMP | ALDH1A1 1649/4885CYP1A2 1268/4885HSD17B10 518/4885 |
| US-20180092913-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
| US-20230302000-A1 | COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS | NES, PSEN1, PSEN2 | ALDH1A1 2409/4885CYP1A2 4390/4885HSD17B10 4301/4885 |
| US-20200246334-A1 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | TYMP, SLC18A3, SLC18A2 | ALDH1A1 318/4885CYP1A2 800/4885HSD17B10 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.